Registries, research, and regrets: is the FDA’s post-marketing REMS process not adequately protecting patients?

Registries, research, and regrets: is the FDA’s post-marketing REMS process not adequately protecting patients?

Bibliographic Details
Main Author:	Norman J. Kachuck
Format:	Article
Language:	English
Published:	SAGE Publishing 2011-11-01
Series:	Therapeutic Advances in Neurological Disorders
Online Access:	https://doi.org/10.1177/1756285611424461

Similar Items

The effects of lobbying on the FDA’s recall classification
by: Yifan Zhou
Published: (2023-06-01)

Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X
by: Sarah Lee, et al.
Published: (2023-11-01)

Restructuring the FDA’s Food Program: Promises and Pitfalls
by: Sammer Marzouk, et al.
Published: (2024-10-01)

FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
by: Muhammad Mazhar Azam, et al.
Published: (2024-12-01)

Content analysis of conversations on Reddit: reactions to FDA’s ENDS prioritized enforcement policy
by: Jamie Guillory, et al.
Published: (2024-09-01)

A Critical Analysis of the FDA’s Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity
by: Sarfaraz K. Niazi
Published: (2023-11-01)

Revisiting FDA’s 1995 Guidance on Bioequivalence Establishment of Topical Dermatologic Corticosteroids: New Research Based Recommendations
by: Deniz Ozdin, et al.
Published: (2018-11-01)

Medical device risk (re)classification: lessons from the FDA’s 515 Program Initiative
by: Joseph S Ross, et al.
Published: (2023-10-01)

The FDA’s New Guideline “Generally Accepted Scientific Knowledge” (GASK): An Opportunity to Expedite the Approval of Biosimilars
by: Sarfaraz K. Niazi
Published: (2023-10-01)

Evaluating adverse effects of environmental agents in food: a brief critique of the US FDA’s criteria
by: Laura N. Vandenberg, et al.
Published: (2023-04-01)

FDA’s proposed rule and its regulatory impact on emerging and reemerging neglected tropical diseases in the United States
by: Alberto E. Paniz-Mondolfi, et al.
Published: (2024-05-01)

Numerical simulation of pulsatile flow through a coronary nozzle model based on FDA’s benchmark geometry
by: Stiehm Michael, et al.
Published: (2017-09-01)

Using the FDA’s Fish and Fishery Products Hazards and Controls Guidance to Develop HACCP Plans for Fish and Fisheries Products
by: Razieh Farzad
Published: (2025-02-01)

Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
by: Qun Li, et al.
Published: (2025-02-01)

SARS-CoV-2 wastewater variant surveillance: pandemic response leveraging FDA’s GenomeTrakr network
by: Ruth E. Timme, et al.
Published: (2024-06-01)

Recent confusion and ongoing actions related to the FDA’s Inactive Ingredient Database (IID) - What should be included in the ANDA?
by: David R. Schoneker
Published: (2016-10-01)

Narrative Review: The FDA’s Perfunctory Approach of Dietary Supplement Regulations Giving Rise to Copious Reports of Adverse Events
by: WeiQi Li, et al.
Published: (2023-03-01)

New science, drug regulation, and emergent public health issues: The work of FDA’s division of applied regulatory science
by: Kimberly Chiu, et al.
Published: (2023-01-01)

Could the vaginal wall sling still have a role after the FDA’s warning? Functional outcomes at 20 years
by: Ester Illiano, et al.
Published: (2022-03-01)

Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development
by: Catherine Mease, et al.
Published: (2024-02-01)

Correction to: Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development
by: Catherine Mease, et al.
Published: (2024-03-01)

Beyond the 510(k): The regulation of novel moderate-risk medical devices, intellectual property considerations, and innovation incentives in the FDA’s De Novo pathway
by: Mateo Aboy, et al.
Published: (2024-02-01)

Thinned and Sparse Beamforming for Semicircular FDAs in the Transmit–Receive Domain
by: Anyi Wang, et al.
Published: (2024-09-01)

Investigating the antecedents of post-purchase regret
by: Huang, Benny Ying Sheng
Published: (2015)

Post-purchase regret in online shopping experience /
by: Nur Adibah Md. Lazim, 1993-, author 612858, et al.
Published: (2018)

Post-purchase regret in online shopping experience /
by: Nur Adibah Md. Lazim, 1993-, author 612858
Published: (2018)

Regret
by: Patton, Winifred

Regret
by: Patton, Winifred

Advancing regulatory science and assessment of FDA REMS programs: A mixed-methods evaluation examining physician survey response
by: Sarah E. Brewer, et al.
Published: (2019-08-01)

Action/inaction and regret : is closeness the moderating effect of regret?
by: Chua, Li Bing., et al.
Published: (2008)

How Impulsivity influences the Post-purchase Consumer Regret?
by: Sokić Katarina, et al.
Published: (2020-11-01)

ABSOLUTE PROTECTION AS A CHARACTERISTIC OF THE RIGHT IN REM
by: O. Budneva
Published: (2011-06-01)

Regrets only /
by: Geary, Nancy, author
Published: (2004)

Reflecting and Regreting
by: Ohad Avny
Published: (2023-12-01)

Sexual Regret
by: Leif Edward Ottesen Kennair, et al.
Published: (2016-12-01)

The Regret Elements Scale: Distinguishing the affective and cognitive components of regret
by: Joshua Buchanan, et al.
Published: (2016-05-01)

The Regret Elements Scale: Distinguishing the affective and cognitive components of regret
by: Joshua Buchanan, et al.
Published: (2016-05-01)

Conflicting interpretations and FDA reputation: the case of post-market surveillance of breast implants
by: Moshe Maor, et al.
Published: (2024-11-01)

The Regret and Disappointment Scale: An instrument for assessing regret and disappointment in decision making
by: Francesco Marcatto, et al.
Published: (2008-01-01)

Local Aspects of Avian Non-REM and REM Sleep
by: Niels C. Rattenborg, et al.
Published: (2019-06-01)